Russian Pharma Market 360°
Information, analytics, consulting, licensing and partnering for international market players
Portfolio analysis & market analytics
Evaluating commercial potential of your portfolio and optimal strategy for Russia and CIS
Matchmaking for products and companies
Profiling and introducing potential partners
Market entry services
Product registration, setting up offices, staffing and commercialization of products
Market Access, GR and state purchases
Customized solutions and regional access
Why you should work with us
We know the industry «inside-out»
All of our employees have years worked in international pharmaceutical companies in managerial positions in Russia, US and Europe in marketing, sales, business development and government relations. We best understand the business environment, opportunities, limitations, requirements and risks. Our reports and services are at international level of quality in terms of content and format.
We have complete and accurate information for making decisions
We work with many databases and sources, local and global, constantly updated. Our information resources include professionals from the industry — service providers, healthcare officials, patient associations, top level managers within companies. Our staff is multilingual allowing for wide scope of research. We and our partners have established footprint in many geographies.
We have our own professional network
We know key decision-makers in charge of corporate operation, licensing and partnering. We have access to key opinion leaders in medical and regulatory fields to aid with making decisions about product or technology prospects. We can easily conduct necessary market research, polls and surveys in order to support and justify strategic or tactical business decisions.
You may find this interesting:
Росздравнадзор внес изменения в порядок проведения фармаконадзора
Росздравнадзор внес изменения в Порядок осуществления фармаконадзора. Документом уточнены сроки, в течение которых Федеральная служба принимает решения об обращении препаратов,…
Правительство направит дополнительно 4,1 млрд рублей на закупку вакцины от гриппа
На закупку вакцины для профилактики гриппа в осенне-зимнем сезоне 2020–2021 годов будет дополнительно направлено 4,1 млрд рублей. Это позволит приобрести еще более 15,5…
Участники рынка выступили за автоматическую разагрегацию кодов лекарственных препаратов
Рабочей группой дистрибьюторов при Росздравнадзоре совместно с ЦРПТ подготовлено предложение по созданию в системе маркировки процедуры автоматической разагрегации. Об…